Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells

Gigliola Sica, Fortunata Iacopino, Gioacchino Robustelli della Cuna, Paolo Marchetti, Luca Marini

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Both tamoxifen and medroxyprogesterone acetate have a direct antitumor effect and are widely used in breast cancer therapy. Luteinizing-hormone-releasing hormone analogs inhibit the growth of breast cancer cells and could represent an alternative treatment for patients affected by breast cancer. Our study was carried out to investigate the effect of leuprorelin (TAP-144) alone or combined with tamoxifen or medroxyprogesterone acetate in human breast cancer cells. Ineffective when used in the absence of estrogens, TAP-144 inhibited the estrogen-stimulated growth of MCF-7, CG-5 and ZR-75-1 cells cultured in medium supplemented with charcoaltreated serum. The growth of estrogen-unresponsive MDA-MB-231 cells was not affected by TAP-144. The combination of TAP-144 with tamoxifen in CG-5 cells did not determine any enhancement of inhibition of cell growth, whereas in both CG-5 and MCF-7 cells, when 1 μM TAP-144 was associated with 0.1 μM medroxyprogesterone acetate, cell growth inhibition was increased, resulting in a subadditive effect. Progesterone receptor levels of CG-5 cells were significantly increased by TAP-144 in the presence of 17β-estradiol with respect to those present in control and 17β-estradiol-treated cells.

Original languageEnglish
Pages (from-to)605-609
Number of pages5
JournalJournal of Cancer Research and Clinical Oncology
Volume120
Issue number10
DOIs
Publication statusPublished - Oct 1994

Fingerprint

Leuprolide
Somatotropin Receptors
Medroxyprogesterone Acetate
Steroid Receptors
Tamoxifen
Estradiol
Breast Neoplasms
Growth
Estrogens
MCF-7 Cells
Progesterone Receptors
Gonadotropin-Releasing Hormone
Cultured Cells

Keywords

  • Breast neoplasms
  • Estrogen and progesterone receptors
  • Leuprorelin
  • Medroxyprogesterone acetate
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells. / Sica, Gigliola; Iacopino, Fortunata; Cuna, Gioacchino Robustelli della; Marchetti, Paolo; Marini, Luca.

In: Journal of Cancer Research and Clinical Oncology, Vol. 120, No. 10, 10.1994, p. 605-609.

Research output: Contribution to journalArticle

Sica, Gigliola ; Iacopino, Fortunata ; Cuna, Gioacchino Robustelli della ; Marchetti, Paolo ; Marini, Luca. / Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells. In: Journal of Cancer Research and Clinical Oncology. 1994 ; Vol. 120, No. 10. pp. 605-609.
@article{f535b7bca0014ac68a4a9d819706f3f5,
title = "Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells",
abstract = "Both tamoxifen and medroxyprogesterone acetate have a direct antitumor effect and are widely used in breast cancer therapy. Luteinizing-hormone-releasing hormone analogs inhibit the growth of breast cancer cells and could represent an alternative treatment for patients affected by breast cancer. Our study was carried out to investigate the effect of leuprorelin (TAP-144) alone or combined with tamoxifen or medroxyprogesterone acetate in human breast cancer cells. Ineffective when used in the absence of estrogens, TAP-144 inhibited the estrogen-stimulated growth of MCF-7, CG-5 and ZR-75-1 cells cultured in medium supplemented with charcoaltreated serum. The growth of estrogen-unresponsive MDA-MB-231 cells was not affected by TAP-144. The combination of TAP-144 with tamoxifen in CG-5 cells did not determine any enhancement of inhibition of cell growth, whereas in both CG-5 and MCF-7 cells, when 1 μM TAP-144 was associated with 0.1 μM medroxyprogesterone acetate, cell growth inhibition was increased, resulting in a subadditive effect. Progesterone receptor levels of CG-5 cells were significantly increased by TAP-144 in the presence of 17β-estradiol with respect to those present in control and 17β-estradiol-treated cells.",
keywords = "Breast neoplasms, Estrogen and progesterone receptors, Leuprorelin, Medroxyprogesterone acetate, Tamoxifen",
author = "Gigliola Sica and Fortunata Iacopino and Cuna, {Gioacchino Robustelli della} and Paolo Marchetti and Luca Marini",
year = "1994",
month = "10",
doi = "10.1007/BF01212815",
language = "English",
volume = "120",
pages = "605--609",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells

AU - Sica, Gigliola

AU - Iacopino, Fortunata

AU - Cuna, Gioacchino Robustelli della

AU - Marchetti, Paolo

AU - Marini, Luca

PY - 1994/10

Y1 - 1994/10

N2 - Both tamoxifen and medroxyprogesterone acetate have a direct antitumor effect and are widely used in breast cancer therapy. Luteinizing-hormone-releasing hormone analogs inhibit the growth of breast cancer cells and could represent an alternative treatment for patients affected by breast cancer. Our study was carried out to investigate the effect of leuprorelin (TAP-144) alone or combined with tamoxifen or medroxyprogesterone acetate in human breast cancer cells. Ineffective when used in the absence of estrogens, TAP-144 inhibited the estrogen-stimulated growth of MCF-7, CG-5 and ZR-75-1 cells cultured in medium supplemented with charcoaltreated serum. The growth of estrogen-unresponsive MDA-MB-231 cells was not affected by TAP-144. The combination of TAP-144 with tamoxifen in CG-5 cells did not determine any enhancement of inhibition of cell growth, whereas in both CG-5 and MCF-7 cells, when 1 μM TAP-144 was associated with 0.1 μM medroxyprogesterone acetate, cell growth inhibition was increased, resulting in a subadditive effect. Progesterone receptor levels of CG-5 cells were significantly increased by TAP-144 in the presence of 17β-estradiol with respect to those present in control and 17β-estradiol-treated cells.

AB - Both tamoxifen and medroxyprogesterone acetate have a direct antitumor effect and are widely used in breast cancer therapy. Luteinizing-hormone-releasing hormone analogs inhibit the growth of breast cancer cells and could represent an alternative treatment for patients affected by breast cancer. Our study was carried out to investigate the effect of leuprorelin (TAP-144) alone or combined with tamoxifen or medroxyprogesterone acetate in human breast cancer cells. Ineffective when used in the absence of estrogens, TAP-144 inhibited the estrogen-stimulated growth of MCF-7, CG-5 and ZR-75-1 cells cultured in medium supplemented with charcoaltreated serum. The growth of estrogen-unresponsive MDA-MB-231 cells was not affected by TAP-144. The combination of TAP-144 with tamoxifen in CG-5 cells did not determine any enhancement of inhibition of cell growth, whereas in both CG-5 and MCF-7 cells, when 1 μM TAP-144 was associated with 0.1 μM medroxyprogesterone acetate, cell growth inhibition was increased, resulting in a subadditive effect. Progesterone receptor levels of CG-5 cells were significantly increased by TAP-144 in the presence of 17β-estradiol with respect to those present in control and 17β-estradiol-treated cells.

KW - Breast neoplasms

KW - Estrogen and progesterone receptors

KW - Leuprorelin

KW - Medroxyprogesterone acetate

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0027978565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027978565&partnerID=8YFLogxK

U2 - 10.1007/BF01212815

DO - 10.1007/BF01212815

M3 - Article

VL - 120

SP - 605

EP - 609

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 10

ER -